| Comprehensive molecular portraits of human breast tumours Cancer Genome Atlas Network Nature 490 (7418), 61-70, 2012 | 7129 | 2012 |
| Circulating tumor cells, disease progression, and survival in metastatic breast cancer M Cristofanilli, GT Budd, MJ Ellis, A Stopeck, J Matera, MC Miller, ... New England Journal of Medicine 351 (8), 781-791, 2004 | 4332 | 2004 |
| Supervised risk predictor of breast cancer based on intrinsic subtypes JS Parker, M Mullins, MCU Cheang, S Leung, D Voduc, T Vickery, ... Journal of clinical oncology 27 (8), 1160-1167, 2009 | 3579 | 2009 |
| Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer MCU Cheang, SK Chia, D Voduc, D Gao, S Leung, J Snider, M Watson, ... JNCI: Journal of the National Cancer Institute 101 (10), 736-750, 2009 | 2403 | 2009 |
| The molecular portraits of breast tumors are conserved across microarray platforms Z Hu, C Fan, DS Oh, JS Marron, X He, BF Qaqish, C Livasy, LA Carey, ... BMC genomics 7 (1), 1-12, 2006 | 1606 | 2006 |
| Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group M Dowsett, TO Nielsen, R A’Hern, J Bartlett, RC Coombes, J Cuzick, ... Journal of the National Cancer Institute 103 (22), 1656-1664, 2011 | 1456 | 2011 |
| Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1–and/or ErbB-2–positive, estrogen receptor–positive primary breast cancer: evidence from a … MJ Ellis, A Coop, B Singh, L Mauriac, A Llombert-Cussac, F Jänicke, ... Journal of Clinical Oncology 19 (18), 3808-3816, 2001 | 1333 | 2001 |
| Genome remodelling in a basal-like breast cancer metastasis and xenograft LI Ding, MJ Ellis, S Li, DE Larson, K Chen, JW Wallis, CC Harris, ... Nature 464 (7291), 999-1005, 2010 | 1190 | 2010 |
| Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer M Cristofanilli, DF Hayes, GT Budd, MJ Ellis, A Stopeck, JM Reuben, ... Journal of Clinical Oncology 23 (7), 1420-1430, 2005 | 1164 | 2005 |
| Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival DF Hayes, M Cristofanilli, GT Budd, MJ Ellis, A Stopeck, MC Miller, ... Clinical Cancer Research 12 (14), 4218-4224, 2006 | 1034 | 2006 |
| Prospective validation of a 21-gene expression assay in breast cancer JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ... New England Journal of Medicine 373 (21), 2005-2014, 2015 | 1002 | 2015 |
| Whole-genome analysis informs breast cancer response to aromatase inhibition MJ Ellis, L Ding, D Shen, J Luo, VJ Suman, JW Wallis, BA Van Tine, ... Nature 486 (7403), 353-360, 2012 | 964 | 2012 |
| Proteogenomic characterization of human colon and rectal cancer B Zhang, J Wang, X Wang, J Zhu, Q Liu, Z Shi, MC Chambers, ... Nature 513 (7518), 382-387, 2014 | 922 | 2014 |
| Proteogenomics connects somatic mutations to signalling in breast cancer P Mertins, DR Mani, KV Ruggles, MA Gillette, KR Clauser, P Wang, ... Nature 534 (7605), 55-62, 2016 | 843 | 2016 |
| Circulating tumor cells versus imaging—predicting overall survival in metastatic breast cancer GT Budd, M Cristofanilli, MJ Ellis, A Stopeck, E Borden, MC Miller, ... Clinical Cancer Research 12 (21), 6403-6409, 2006 | 823 | 2006 |
| Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study W Eiermann, S Paepke, J Appfelstaedt, A Llombart-Cussac, J Eremin, ... Annals of Oncology 12 (11), 1527-1532, 2001 | 817 | 2001 |
| Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ... New England Journal of Medicine 379 (2), 111-121, 2018 | 801 | 2018 |
| Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on … CK Osborne, J Pippen, SE Jones, LM Parker, M Ellis, S Come, SZ Gertler, ... Journal of Clinical Oncology 20 (16), 3386-3395, 2002 | 756 | 2002 |
| Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in … HA Burris III, HI Hurwitz, EC Dees, A Dowlati, KL Blackwell, B O'neil, ... Journal of Clinical Oncology 23 (23), 5305-5313, 2005 | 746 | 2005 |
| A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor–positive breast cancer TO Nielsen, JS Parker, S Leung, D Voduc, M Ebbert, T Vickery, SR Davies, ... Clinical Cancer Research 16 (21), 5222-5232, 2010 | 689 | 2010 |
Torsten NielsenProfessor of Pathology, University of British ColumbiaVerified email at mail.ubc.ca
